Page last updated: 2024-09-03

t 0632 and Pancreatitis

t 0632 has been researched along with Pancreatitis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Endo, T; Nagasaki, M; Shikano, T; Taniguchi, H; Yazaki, N; Yomota, E1
Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E1
Grendell, JH; Niederau, C1

Other Studies

3 other study(ies) available for t 0632 and Pancreatitis

ArticleYear
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    European journal of pharmacology, 1996, Sep-26, Volume: 312, Issue:2

    Topics: Animals; Benzodiazepinones; Ceruletide; Devazepide; Dogs; Female; Gastric Emptying; Indoles; Male; Pancreas; Pancreatitis; Pregnancy; Proglumide; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Sincalide

1996
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Japanese journal of pharmacology, 1997, Volume: 73, Issue:2

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate; Guanidines; Hormone Antagonists; Indoles; Ligation; Male; Pancreatic Ducts; Pancreatitis; Proglumide; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Cholecystokinin A; Receptors, Cholecystokinin

1997
Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists.
    Digestion, 1999, Volume: 60 Suppl 1

    Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Devazepide; Disease Models, Animal; Disease Progression; Humans; Indoles; Pancreatitis; Rats; Receptors, Cholecystokinin

1999